R. Ptak

发表

Human immunodeficiency virus type 1, human protein interaction database at NCBI

Donna R. Maglott, Kim D. Pruitt, Kenneth S. Katz, 2008, Nucleic Acids Res..

Cataloguing the HIV type 1 human protein interaction network.

David L Robertson, William Fu, Brigitte E. Sanders-Beer, 2008, AIDS research and human retroviruses.

HIV-host interactions: a map of viral perturbation of the host system.

David L Robertson, William Fu, Brigitte E. Sanders-Beer, 2009, AIDS.

Inhibiting Early-Stage Events in HIV-1 Replication by Small-Molecule Targeting of the HIV-1 Capsid

R. Ptak, J. Sodroski, F. Krebs, 2012, Journal of Virology.

Potent and broad neutralizing activity of a single chain antibody fragment against cell-free and cell-associated HIV-1

R. Ptak, B. Haynes, D. Dimitrov, 2010, mAbs.

Methylenecyclopropane analogues of nucleosides: synthesis, absolute configuration, and enantioselectivity of antiviral effect of (R)-(-)- and (S)-(+)-synadenol.

R. Ptak, A. Camerman, N. Camerman, 1999, Nucleosides & nucleotides.

Development of a Comprehensive Human Immunodeficiency Virus Type 1 Screening Algorithm for Discovery and Preclinical Testing of Topical Microbicides

Brigitte E. Sanders-Beer, B. Sanders-Beer, R. Ptak, 2008, Antimicrobial Agents and Chemotherapy.

Mechanisms of Human Immunodeficiency Virus Type 2 RNA Packaging: Efficient trans Packaging and Selection of RNA Copackaging Partners

W. Fu, R. Ptak, Jianbo Chen, 2011, Journal of Virology.

Development of Real-Time PCR Array for Simultaneous Detection of Eight Human Blood-Borne Viral Pathogens

R. Ptak, G. Hung, Bingjie Li, 2012, PloS one.

Correlation of Naturally Occurring HIV-1 Resistance to DEB025 with Capsid Amino Acid Polymorphisms

R. Ptak, B. Rosenwirth, P. Gallay, 2013, Viruses.

Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size

Daniel I. S. Rosenbloom, Michele D. Sobolewski, R. Ptak, 2019, PLoS computational biology.

Novel Compound Inhibitors of HIV-1NL4-3 Vpu

Marc C. Johnson, R. Ptak, R. Bostwick, 2022, Viruses.

Novel Compound Inhibitors of HIV-1NL4-3 Vpu

Marc C. Johnson, R. Ptak, R. Bostwick, 2021, bioRxiv.

Highly Potent Chimeric Inhibitors Targeting Two Steps of HIV Cell Entry*

R. Ptak, P. LiWang, M. Mankowski, 2011, The Journal of Biological Chemistry.

R430: A potent inhibitor of DNA and RNA viruses

R. Yolken, R. Ptak, A. Chattopadhyay, 2018, Scientific Reports.

Au(iii) compounds as HIV nucleocapsid protein (NCp7)-nucleic acid antagonists.

R. Ptak, N. Farrell, D. Fabris, 2016, Chemical communications.

Cross-reactive HIV-1-neutralizing activity of serum IgG from a rabbit immunized with gp41 fused to IgG1 Fc: possible role of the prolonged half-life of the immunogen.

R. Ptak, D. Dimitrov, Yanping Wang, 2009, Vaccine.

Structure–Activity Relationship Studies of Indole-Based Compounds as Small Molecule HIV-1 Fusion Inhibitors Targeting Glycoprotein 41

R. Ptak, M. Gochin, H. Kaur, 2014, Journal of medicinal chemistry.

Discovery and optimization of novel small-molecule HIV-1 entry inhibitors using field-based virtual screening and bioisosteric replacement.

R. Ptak, N. Madani, Amy M. Princiotto, 2014, Bioorganic & medicinal chemistry letters.

Evaluation of PD 404,182 as an Anti-HIV and Anti-Herpes Simplex Virus Microbicide

R. Ptak, Zhilei Chen, P. Gallay, 2013, Antimicrobial Agents and Chemotherapy.

Bifunctional aryloxyphosphoramidate prodrugs of 2'-C-Me-uridine: synthesis and anti-HCV activity.

R. Ptak, P. Herdewijn, M. Murray, 2016, Organic & biomolecular chemistry.

HBV Core Promoter Inhibition by Tubulin Polymerization Inhibitor (SRI-32007)

R. Ptak, M. Suto, Zhaohui Cai, 2020, Advances in virology.

An analog of camptothecin inactive against Topoisomerase I is broadly neutralizing of HIV-1 through inhibition of Vif-dependent APOBEC3G degradation.

R. Ptak, HaroldC. Smith, R. Buckheit, 2016, Antiviral research.

Synthesis and antiviral activity of phosphoralaninate derivatives of methylenecyclopropane analogues of nucleosides.

R. Ptak, Y. Cheng, E. Kern, 1999, Antiviral research.

Enhanced potency of bivalent small molecule gp41 inhibitors.

R. Ptak, M. Gochin, H. Kaur, 2017, Bioorganic & medicinal chemistry.

Reshaping an Acyclic Nucleoside Phosphonate into a Selective Anti-hepatitis B Virus Compound.

R. Ptak, P. Herdewijn, B. Korba, 2022, Journal of medicinal chemistry.

Identification of a Novel HIV-1 Inhibitor Targeting Vif-dependent Degradation of Human APOBEC3G Protein*

Erez Pery, R. Ptak, N. M. Nebane, 2015, The Journal of Biological Chemistry.

Albumin-conjugated C34 Peptide HIV-1 Fusion Inhibitor

R. Ptak, C. Stoddart, S. Galkina, 2008, Journal of Biological Chemistry.

Phosphorylation of β-d-Ribosylbenzimidazoles Is Not Required for Activity against Human Cytomegalovirus

R. Ptak, M. Nassiri, P. Krosky, 2002, Antimicrobial Agents and Chemotherapy.

Inhibitors of HIV-1 Nef-Mediated Activation of the Myeloid Src-Family Kinase Hck Block HIV-1 Replication in Macrophages and Disrupt MHC-I Downregulation.

R. Ptak, S. Du, T. Smithgall, 2022, ACS infectious diseases.

Inhibition of Human Immunodeficiency Virus Type 1 by Triciribine Involves the Accessory Protein Nef

R. Ptak, K. Watson, R. Buckheit, 2010, Antimicrobial Agents and Chemotherapy.

Inhibition ofHumanCytomegalovirus inCulture byAlkenyl Guanine Analogs oftheThiazolo(4,5-d)P yrimidineSystem

R. Ptak, J. Huffman, J. Drach, 1994 .

Synergistic antiviral activity of Sofosbuvir and type‐I interferons (α and β) against Zika virus

S. Goebel, R. Ptak, B. Snyder, 2018, Journal of medical virology.

Amidate Prodrugs of Deoxythreosyl Nucleoside Phosphonates as Dual Inhibitors of HIV and HBV Replication.

R. Ptak, C. Pannecouque, P. Herdewijn, 2016, Journal of medicinal chemistry.

Application of the synthetic aminosugars for glycodiversification: synthesis and antimicrobial studies of pyranmycin.

R. Ptak, J. Takemoto, Yu Hui, 2004, The Journal of organic chemistry.

Structure–Activity Relationships of a Novel Capsid Targeted Inhibitor of HIV-1 Replication

Sandhya Kortagere, Roger G. Ptak, Jimmy P. Xu, 2014, J. Chem. Inf. Model..

Inhibition of Human Cytomegalovirus Replication by Benzimidazole Nucleosides Involves Three Distinct Mechanisms

R. Ptak, Brian T. Emmer, D. Evers, 2004, Antimicrobial Agents and Chemotherapy.

Differences in DNA Packaging Genes and Sensitivity to Benzimidazole Ribonucleosides between Human Cytomegalovirus Strains AD169 and Towne

R. Ptak, P. Krosky, L. Townsend, 2000, Antiviral chemistry & chemotherapy.

Hexamminecobalt (III) Chloride as a Broad-Spectrum Antiviral Complex

R. Ptak, G. Olinger, L. Hensley, 2011 .

HIV integrase inhibitors with nucleobase scaffolds: discovery of a highly potent anti-HIV agent.

R. Ptak, N. Neamati, V. Nair, 2006, Journal of medicinal chemistry.

Synthesis and antiviral evaluation of halogenated beta-D- and -L-erythrofuranosylbenzimidazoles.

R. Ptak, N. Lippa, J. Tidwell, 2000, Journal of medicinal chemistry.

Development of indole compounds as small molecule fusion inhibitors targeting HIV-1 glycoprotein-41.

R. Ptak, M. Gochin, H. Kaur, 2011, Journal of medicinal chemistry.

Nucleosides with self-complementary hydrogen-bonding motifs: synthesis and base-pairing studies of two nucleosides containing the imidazo[4,5-d]pyridazine ring system.

R. Ptak, R. Hosmane, R. K. Ujjinamatada, 2006, Bioorganic & medicinal chemistry.

Synthesis of novel guanidine incorporated aminoglycosides, guanidinopyranmycins

R. Ptak, Yu Hui, C. Chang, 2002 .

HIV-1, human interaction database: current status and new features

Guangfeng Song, J. Rodney Brister, Dakshesh Darji, 2014, Nucleic Acids Res..

Broad spectrum antimicrobial activity of leukocyte extracts from the American alligator (Alligator mississippiensis).

R. Ptak, Mark Merchant, Kaili Mills, 2006, Veterinary immunology and immunopathology.

Antiviral activity of serum from the American alligator (Alligator mississippiensis).

R. Ptak, Mark Merchant, Jay B. Wells, 2005, Antiviral research.

Synthesis and antiproliferative and antiviral activity of 2'-deoxy-2'-fluoroarabinofuranosyl analogs of the nucleoside antibiotics toyocamycin and sangivamycin.

R. Ptak, S. Krawczyk, M. Nassiri, 1995, Journal of medicinal chemistry.

IMU-838, a Developmental DHODH Inhibitor in Phase II for Autoimmune Disease, Shows Anti-SARS-CoV-2 and Broad-Spectrum Antiviral Efficacy In Vitro

R. Ptak, K. Überla, A. Muehler, 2020, Viruses.

Antiviral activity of hop constituents against a series of DNA and RNA viruses.

R. Ptak, T. Voss, Robert J. Smith, 2004, Antiviral research.

(Z)- and (E)-2-((hydroxymethyl)cyclopropylidene)methyladenine and -guanine. New nucleoside analogues with a broad-spectrum antiviral activity.

R. Ptak, Y. Cheng, Ju-sheng Lin, 1998, Journal of medicinal chemistry.

Expanding the Antiviral Spectrum of 3-Fluoro-2-(phosphonomethoxy)propyl Acyclic Nucleoside Phosphonates: Diamyl Aspartate Amidate Prodrugs.

R. Ptak, P. Herdewijn, M. Luo, 2017, Journal of medicinal chemistry.

Redoxal, an inhibitor of de novo pyrimidine biosynthesis, augments APOBEC3G antiviral activity against human immunodeficiency virus type 1.

Erez Pery, R. Ptak, A. Sheehy, 2015, Virology.

Inhibition of human cytomegalovirus in culture by alkenyl guanine analogs of the thiazolo[4,5-d]pyrimidine ring system

R. Ptak, G. R. Revankar, J. Huffman, 1994, Antimicrobial Agents and Chemotherapy.

Synthesis of non-nucleoside analogs of toyocamycin, sangivamycin, and thiosangivamycin: the effect of certain 4- and 4,6-substituents on the antiviral activity of pyrrolo[2,3-d]pyrimidines.

R. Ptak, C. Kennedy, T. Renau, 1996, Journal of Medicinal Chemistry.

Deoxy sugar analogues of triciribine: correlation of antiviral and antiproliferative activity with intracellular phosphorylation.

L B Townsend, A R Porcari, R. Ptak, 2000, Journal of medicinal chemistry.

Introduction of a cyano group at the 2-position of an (R,S)-3-hydroxy-2-(phosphonomethoxy)propyl (HPMP) derivative of thymine elicits selective anti-HBV activity.

R. Ptak, P. Herdewijn, M. Prichard, 2021, RSC medicinal chemistry.

(R)-(-)- and (S)-(+)-Synadenol: synthesis, absolute configuration, and enantioselectivity of antiviral effect.

R. Ptak, A. Camerman, N. Camerman, 1998, Journal of medicinal chemistry.

(Z)‐ and (E)‐2‐((Hydroxymethyl)cyclopropylidene)methyladenine and ‐guanine. New Nucleoside Analogues with a Broad‐Spectrum Antiviral Activity.

R. Ptak, Ju-sheng Lin, E. Kern, 1998 .

Synthesis, antiviral activity, and mode of action of some 3-substituted 2,5,6-trichloroindole 2'- and 5'-deoxyribonucleosides.

R. Ptak, L. Townsend, J. Drach, 2004, Journal of medicinal chemistry.

Phosphorothioate Oligonucleotides Inhibit Human Immunodeficiency Virus Type 1 Fusion by Blocking gp41 Core Formation

R. Ptak, Hong Lu, Shibo Jiang, 2006, Antimicrobial Agents and Chemotherapy.

A novel anti-HIV active integrase inhibitor with a favorable in vitro cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase metabolism profile.

R. Ptak, V. Nair, Maurice O Okello, 2013, Antiviral research.

Inhibition of Human Immunodeficiency Virus Type 1 Replication in Human Cells by Debio-025, a Novel Cyclophilin Binding Agent

R. Ptak, E. De Clercq, B. Rosenwirth, 2008, Antimicrobial Agents and Chemotherapy.

Synthesis of Non-Nucleoside Analogues of Toyocamycin, Sangivamycin, and Thiosangivamycin: The Effect of Certain 4- and 4,6-Substituents on the Antiviral Activity of Pyrrolo(2,3-d)pyrimidines.

R. Ptak, C. Kennedy, T. Renau, 2010 .

Synthesis and Antiviral Activity of 2-Substituted Analogs of Triciribine

R. Ptak, J. Breitenbach, K. Borysko, 2003, Nucleosides, nucleotides & nucleic acids.

Acyclic sugar analogs of triciribine: lack of antiviral and antiproliferative activity correlate with low intracellular phosphorylation.

R. Ptak, J. Breitenbach, K. Borysko, 1999, Nucleosides & nucleotides.

Phosphorylation of triciribine is necessary for activity against HIV type 1.

L B Townsend, A R Porcari, R. Ptak, 1998, AIDS research and human retroviruses.

Resistance of Human Cytomegalovirus to Benzimidazole Ribonucleosides Maps to Two Open Reading Frames: UL89 and UL56

R. Ptak, P. Krosky, L. Townsend, 1998, Journal of Virology.

Molecular evidence of HIV-1 transmission in a criminal case

David P. Mindell, Richard A. Gibbs, Roger G. Ptak, 2002, Proceedings of the National Academy of Sciences of the United States of America.

HIV-1 regulatory proteins: targets for novel drug development

R. Ptak, 2002, Expert opinion on investigational drugs.

Moloney Leukemia Virus 10 (MOV10) Protein Inhibits Retrovirus Replication*

W. Fu, R. Ptak, Xiaojun Wang, 2010, The Journal of Biological Chemistry.

Suboptimal inhibition of protease activity in human immunodeficiency virus type 1: effects on virion morphogenesis and RNA maturation.

K. Nagashima, W. Fu, R. Ptak, 2008, Virology.

Inhibition of HIV-1 Replication by Amphotericin B Methyl Ester

R. Ptak, E. Freed, A. Waheed, 2006, Journal of Biological Chemistry.

Heterocyclic Compounds That Inhibit Rev-RRE Function and Human Immunodeficiency Virus Type 1 Replication

R. Ptak, D. Rekosh, Sharmila Raman, 2008, Antimicrobial Agents and Chemotherapy.

Naturally Occurring Capsid Substitutions Render HIV-1 Cyclophilin A Independent in Human Cells and TRIM-cyclophilin-resistant in Owl Monkey Cells*

R. Ptak, R. Stanfield, B. Rosenwirth, 2005, Journal of Biological Chemistry.

Exploring Modifications of an HIV-1 Capsid Inhibitor: Design, Synthesis, and Mechanism of Action.

Jimmy P. Xu, R. Ptak, G. Melikyan, 2018, Journal of drug design and research.

Development of Hexadecyloxypropyl Tenofovir (CMX157) for Treatment of Infection Caused by Wild-Type and Nucleoside/Nucleotide-Resistant HIV

R. Ptak, G. Painter, R. Buckheit, 2010, Antimicrobial Agents and Chemotherapy.

Nucleoside / Nucleotide-Resistant HIV Infection Caused by Wild-Type and Tenofovir ( CMX 157 ) for Treatment of Development of Hexadecyloxypropyl

R. Ptak, G. Painter, R. Lanier, 2010 .

Identification of a Small‐Molecule Inhibitor of HIV‐1 Assembly that Targets the Phosphatidylinositol (4,5)‐bisphosphate Binding Site of the HIV‐1 Matrix Protein

R. Ptak, P. Fedichev, S. Cocklin, 2013, ChemMedChem.

Effector memory differentiation increases detection of replication-competent HIV-l in resting CD4+ T cells from virally suppressed individuals

R. Ptak, M. Busch, S. Deeks, 2019, PLoS pathogens.

OP 5.4 – 00127 Identification and characterization of novel inhibitors of HIV Tat protein

R. Ptak, Susan M. Schader, S. Valente, 2022, Journal of virus eradication.

Assessing intra-lab precision and inter-lab repeatability of outgrowth assays of HIV-1 latent reservoir size

Michael P. Busch, Jun Lai, John W. Mellors, 2018, bioRxiv.

Discovery of a small-molecule antiviral targeting the HIV-1 matrix protein.

R. Ptak, P. Fedichev, S. Cocklin, 2013, Bioorganic & medicinal chemistry letters.

Dimer Initiation Signal of Human Immunodeficiency Virus Type 1: Its Role in Partner Selection during RNA Copackaging and Its Effects on Recombination

William Fu, Roger G. Ptak, Jianbo Chen, 2007, Journal of Virology.

Potent Strategy To Inhibit HIV-1 by Binding both gp120 and gp41

R. Ptak, P. LiWang, M. Mankowski, 2010, Antimicrobial Agents and Chemotherapy.

Identification of Heterocyclic Compounds that Inhibit Rev-RRE Function and Human Immunodeficiency Virus Type-1 Replication Running title: Compounds that Inhibit HIV Rev Function

R. Ptak, D. Rekosh, Sharmila Raman, 2008 .

Dimeric RNA Recognition Regulates HIV-1 Genome Packaging

William Fu, Roger G. Ptak, Kunio Nagashima, 2013, PLoS pathogens.

A single β-octyl glucoside molecule induces HIV-1 Nef dimer formation in the absence of partner protein binding

R. Ptak, T. Smithgall, J. Alvarado, 2018, PloS one.

Resistance of Human Cytomegalovirus to the Benzimidazole l-Ribonucleoside Maribavir Maps to UL27

R. Ptak, L. Townsend, J. Drach, 2003, Journal of Virology.

Open Reading Frames: UL89 and UL56 Benzimidazole Ribonucleosides Maps to Two Resistance of Human Cytomegalovirus to

R. Ptak, L. Townsend, J. Westerman, 2013 .

Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size

Daniel I. S. Rosenbloom, R. Ptak, D. Richman, 2020, The Journal of infectious diseases.

Investigation of the molecular characteristics of bisindole inhibitors as HIV-1 glycoprotein-41 fusion inhibitors.

R. Ptak, M. Gochin, Shidong Chu, 2019, European journal of medicinal chemistry.

A sensitive virus yield assay for evaluation of Antivirals against Zika Virus.

S. Goebel, R. Ptak, R. Bostwick, 2016, Journal of virological methods.

Antiviral activity of CHO-SS cell-derived human omega interferon and other human interferons against HCV RNA replicons and related viruses.

R. Ptak, Jay B. Wells, C. Scribner, 2007, Antiviral research.

Multivalent binding oligomers inhibit HIV Tat-TAR interaction critical for viral replication.

R. Ptak, K. Jeang, P. Legault, 2009, Bioorganic & medicinal chemistry letters.

In vitro resistance development for RO-0335, a novel diphenylether nonnucleoside reverse transcriptase inhibitor.

R. Ptak, N. Cammack, H. Javanbakht, 2010, Antiviral research.

Scalable Synthesis, In Vitro cccDNA Reduction, and In Vivo Antihepatitis B Virus Activity of a Phosphonomethoxydeoxythreosyl Adenine Prodrug.

R. Ptak, P. Herdewijn, M. Luo, 2020, Journal of medicinal chemistry.

Application of ultrasensitive digital ELISA for p24 enables improved evaluation of HIV-1 reservoir diversity and growth kinetics in viral outgrowth assays

R. Ptak, C. Lackman-Smith, S. Bakkour, 2023, Scientific reports.

Corrigendum to “Degradation of Quillaja saponaria Molina saponins: Loss of the protective effects of a herpes simplex virus 1 subunit vaccine” [International Immunopharmacology 2/12 (2002) 1703–1711]

R. Ptak, R. Reynolds, T. Voss, 2005 .

Assessing the Suitability of Next-Generation Viral Outgrowth Assays to Measure Human Immunodeficiency Virus 1 Latent Reservoir Size

Daniel I. S. Rosenbloom, R. Ptak, D. Richman, 2020, The Journal of Infectious Diseases.